Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 May 2010

Allred D Craig

Abstract excerpt

There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERalpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Genes, erbB-2

Share to Genetic Predisposition to Disease

Share to Immunohistochemistry

Share to Receptor, ErbB-2

Share to Receptors, Progesterone

Source

Identifiers

PMID: 20436503
DOI: 10.1038/modpathol.2010.55

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.PMID 20436503Read ↗

Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An updateSemantic proximity Read ↗

The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.Semantic proximity Read ↗

Breast cancer biomarkers and molecular medicine.Semantic proximity Read ↗

Advances in prognostic and predictive biomarkers for breast cancer: Integrating multigene assays, hormone receptors, and emerging circulating biomarkersSemantic proximity Read ↗

Current and emerging breast cancer biomarkersSemantic proximity Read ↗

Biomarker assessment and molecular testing for prognostication in breast cancerSemantic proximity Read ↗

Prognostic molecular markers in early breast cancerSemantic proximity Read ↗

Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendationsSemantic proximity Read ↗

Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.Semantic proximity Read ↗

Bringing molecular prognosis and prediction to the clinic.Semantic proximity Read ↗

The loss of progesterone receptor predicts more aggressive biological features and worse outcomes in estrogen receptor-positive and HER2-negative inflammatory breast cancerSemantic proximity Read ↗

Estrogen receptor-beta and breast cancer: Translating biology into clinical practiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.